IMPACT Medicom

Dans cet épisode du balado, Dre Geneviève Matte discutera de la prise en charge des patients atteints d'amyloïdose à transthyrétine héréditaire à phénotype mixte tout au cours de leur maladie, des premiers symptômes jusqu'au suivi des patients sous traitement. Pour plus de détails, veuillez consulter la publication connexe du Dre Matte et de ses collègues : https://www.sciencedirect.com/science/article/pii/S2589790X25001180 À propos de notre invité : Dre Geneviève Matte est neurologue-chercheure au Centre Hospitalier de l'Université de Montréal-Centre de Recherche du CHUM et professeure adjoint de clinique au Département de neurosciences de l'Université de Montréal depuis 2010.  Elle a obtenu son diplôme de médecine de l'Université McGill en 2003, puis a réussi sa résidence en neurologie adulte à l'Université de Montréal en 2008. Dre Matte a ensuite acquis une expertise en médecine neuromusculaire à la Cleveland Clinic Foundation à Cleveland, Ohio. Depuis 2013, elle est directrice de la Clinique SLA et des maladies du neurone moteur du CHUM.  Elle est aussi leader pour la neurologie dans le programme de référence en amyloïdose du CHUM, recevant des consultations de toute la province.  De 2020 à 2024, Dre Matte a été co-présidente du Réseau Canadien de Recherche en SLA (CALS).  Elle est désormais membre du comité exécutif de la Société Canadienne d'Amyloïdose.Cet épisode du balado a été commanditée par AstraZeneca Canada. Pour d'autres contenus éducatifs médicaux, veuillez vous abonner à notre balado ou visitez notre site web à l'adresse suivante : https://www.impactmedicom.com (https://www.impactmedicom.com/). 

In this podcast episode, Dr. Diego Delgado discusses how to manage patients with mixed phenotype hereditary transthyretin amyloidosis over the course of their disease from initial symptoms and clinical suspicion, to monitoring patients on treatment. For additional details, please see the related video publication by Dr. Delgado and colleagues: https://www.sciencedirect.com/science/article/pii/S2589790X25001180Our Guest: Dr. Diego Delgado is the Director of the Cardiac Amyloid Centre and Associate Professor in the Division of Cardiology and Cardiac Transplantation at the University Health Network in Toronto, Ontario. Dr. Diego Delgado graduated in Medicine from the Universidad del Salvador in Buenos Aires, Argentina. He completed his Internal Medicine and Cardiology training in Hospital Espanol in Buenos Aires. Subsequently he completed a research fellowship in cardiac transplantation at Rush Presbyterian St Luke's Medical Center in Chicago, US and a research/clinical fellowship in heart failure and transplantation at the Toronto General Hospital.Dr. Delgado completed his Maters of Science in Clinical Epidemiology at the University of Toronto and the Leadership Development Program at Rotman School of Management in Toronto. He is the author of more than 100 publications in the area of heart failure, transplantation and mechanical assist devices. His interests are immunologic aspects of heart failure and transplantation and cardio oncology.This podcast episode was sponsored by AstraZeneca Canada. For other medical education content, please subscribe to our podcast or visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

(FRENCH) In this podcast episode, which follows this introduction in French, Dr Christopher Lemieux summarizes a paper by Dr Abramson, et al. on the management of Peripheral Neuropathy Associated with Brentuximab Vedotin in the Frontline Treatment of classical Hodgkin Lymphoma.Our GuestDr Lemieux is a Hematologist at the Centre hospitalier universitair de Québec-Université Laval. He is also a member of the immunocellular therapy network fellowship program at Université Laval. This podcast episode was sponsored by Pfizer Canada Inc.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

In this podcast episode, Dr. Michael Chu discusses the management of peripheral neuropathy associated with the use of brentuximab vedotin for the first-line treatment of classical Hodgkin Lymphoma. Our GuestDr. Michael Chu is a clinician scientist at the Cross Cancer Institute and an Associate Professor at the University of Alberta in Edmonton, Alberta.This podcast episode was sponsored by Pfizer Canada Inc.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

In this podcast episode, Dr. Versha Banerji, a Canadian hematologist from Manitoba and Dr. Jennifer Brown, an internationally renowned hematologist from the United States, discuss data on the treatment of CLL presented at the American Society of Hematology (or ASH) meeting in San Diego, CA. The discussion involves an analysis of the data from 8 presentations on combination and novel therapies for the treatment of CLL. In this discussion, the data is put into the Canadian context, with key take-aways that are relevant to practice in Canada.  Our Guests:Dr. Versha Banerji is a hematologist at Max Rady College of Medicine at the University of Manitoba in Winnipeg, Manitoba.Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.This podcast episode was sponsored by BeiGene Canada ULC.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL. Our Guest:Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Research Institute in Oncology and Hematology, based in Winnipeg, Manitoba.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.comThis episode was funded by Eli Lilly, Canada. 

In this podcast episode, three of Canada's top hematologists discuss data on the treatment of CLL presented at the European Hematology Association (or EHA) meeting in Madrid, Spain. The discussion involves an analysis of the data from 6 oral presentations on combination and novel therapies for the treatment of CLL. In this discussion, the data is put into the Canadian context, with key take-aways that are relevant to practice in Canada.  Our Guests:Dr. Versha Banerji from Max Rady College of Medicine at the University of Manitoba in Winnipeg, Manitoba chairs the meeting. Dr. Banerji is joined by Dr Sarit Assouline, from the Jewish General Hospital in Montreal, Quebec and Dr. Christopher Hillis, from McMaster University in Hamilton, Ontario. If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/)

In this episode of our podcast, recorded at the European Hematology Association (EHA) meeting in Madrid, Spain, we discuss  updated results of the BGB-11417-101 trial with Dr. Stephen Opat. The BGB-11417-101 trial examined the efficacy and safety of sonrotoclax plus zanubrutinib for the treatment of R/R CLL. Our Guest:Dr. Stephen Opat is the director of Clinical Haematology at Monash Health, founder and chair of the Australasian Lymphoma and Related Diseases Registry and lead investigator of the Melbourne Genomics Health Alliance Lymphoma Flagship.This podcast episode was sponsored by BeiGene Canada ULC.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this episode, Dr. Barbara Melosky discusses cutting edge approaches to the treatment of Lung Cancer, including the use of artificial intelligence and novel therapeutic approaches such as cancer vaccines and new targeted therapies.Our Guest:Dr. Barbara MeloskyDr Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group and is creator and chair of the British Columbia Lung Cancer Biobank. This podcast episode was sponsored by Sanofi Aventis Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to our podcast episode on diagnostic, prognostic and predictive biomarkers for the treatment of upper GI cancers. In this episode, Dr Brezden-Masley (medical oncologist) and Dr Streutker (pathologist) discuss the latest biomarkers that may inform treatment of upper GI cancer. Our Guests:Dr. Christine Brezden-MasleyDr.  Brezden-Masley is a Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital as well as the Medical Director of Cancer Program for Sinai Health System in Toronto, Canada. Dr. Catherine StreutkerDr.  Streutker is a Professor in the Department of Laboratory Medicine & Pathobiology at the University of Toronto.This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this video capsule, Dr. Mark Taylor discusses the surgical implications for the treatment of cSCC. This podcast episode is best viewed alongside the slides, which can be found in the video capsule version: https://www.youtube.com/watch?v=uk5JEUjbkDE&t=127s.  Our Guest:Dr. S. Mark Taylor is a Facial Plastic and Reconstructive surgeon in Halifax, Nova Scotia. He is currently a Professor of Surgery at Dalhousie University. His expertise and clinical interest includes rhinoplasty/nasal surgery, eyelid surgery, management of facial paralysis, facial skin cancer, facial reconstruction, and surgery of the aging face.Note: The faculty for this program had full editorial control of the content.The following program was funded by Sanofi.Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing the product always refer to the latest Product Monograph, available at www.Sanofi.ca.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this podcast episode, Dr. Evan Lipson discusses the use of immunotherapy for patients with skin cancer who have had a kidney transplant. Our guest:Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease.Note: The faculty for this program had full editorial control of the content.The following program was funded by Sanofi.Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing the product always refer to the latest Product Monograph, available at www.Sanofi.ca.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this podcast episode, Dr. Rami Kotb and Dr. Donna Reece discuss results of the CMRG Isa-CYBORD trial presented at the ASH 2023 meeting, and the implications of the results for Canadian clinical practice.Our Guests:Dr. Rami Kotb is a physician in the Division of Hematology, Department of Medical Oncology & Hematology at CancerCare Manitoba, Winnipeg, MB, CanadaDr Donna Reece is the Director and a Professor of Medicine in the Program for Multiple Myeloma and Related Diseases at the University Health Network. She is also a Professor of Medicine at the University of Toronto and Princess Margaret Hospital in Toronto, ON, CanadaNote: A link to the abstract at ASH can be found here: https://ash.confex.com/ash/2023/webprogram/Paper190168.htmlThis podcast episode was sponsored by Sanofi-Aventis Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this episode of our podcast, recorded at the American Society of Hematology (ASH) in San Diego, California, we discuss  updated results of the ALPINE trial with Dr. Jennifer Brown. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL. Our Guest:Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.Note: The ALPINE trial is published in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.This podcast episode was sponsored by BeiGene Canada ULC.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this video capsule series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada.This fifth episode of the series was recorded live from ESMO 2023 with Dr. Thomas Powles, who presented results of the EV-302 trial, and Dr. Normand Blais, Dr. Srikala Sridhar, and Dr. Bernie Eigl, who discussed the impact of new data from trials on 1L LA/mUC .Our Guests:Dr. Thomas Powles: Dr Thomas Powles is a Professor of Genitourinary Oncology and Director of the Barts Cancer Centre at St. Bartholomew's Hospital. He is also the Lead for Solid Tumour Research in London, England. Dr. Normand Blais: Dr  Blais is the co-founder of the Groupe d'Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.Dr. Srikala Sridhar: Dr  Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers. Dr. Bernie Eigl: Dr. Eigl is a medical oncologist specializing in genitourinary oncology, with a special research interest in bladder and prostate cancers at BC Cancer. He ia alo a Clinical Associate Professor at the University of British Columbia.This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto.In this fourth and final episode taken from the webinar, Drs Normand Blais, Terence Friedlander, and Srikala Sridhar provide their perspective on the management of the first-line treatment locally advanced metastatic urothelial carcinoma, including a discussion of the optimal use of enfortumab vedotin plus pembrolizumab and management of associated adverse events. Our Guests:Dr. Normand Blais: Dr  Blais is the co-founder of the Groupe d'Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.Dr. Terence Friedlander: Dr  Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases.Dr. Srikala Sridhar: Dr  Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto.In this third episode taken from the webinar, Dr. Srikala Sridhar presents a clinical case on the treatment of locally advanced metastatic urothelial carcinoma, highlighting the role of enfortumab vedotin plus pembrolizumab in the treatment plan. Our Guests:Dr. Normand Blais: Dr  Blais is the co-founder of the Groupe d'Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.Dr. Terence Friedlander: Dr  Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases.Dr. Srikala Sridhar: Dr  Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto.In this second episode taken from the webinar, Dr. Terrence Friedlander presents clinical data in the first-line setting and provides a US perspective on how he manages the treatment of locally advanced metastatic urothelial carcinoma.  Our Guests:Dr. Normand Blais: Dr  Blais is the co-founder of the Groupe d'Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.Dr. Terence Friedlander: Dr  Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases.Dr. Srikala Sridhar: Dr  Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto. In this first episode taken from the webinar, Dr. Normand Blais introduces the speakers and discusses the unmet needs of patients with locally advanced metastatic urothelial carcinoma in Canada. Our Guests:Dr. Normand Blais: Dr  Blais is the co-founder of the Groupe d'Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.Dr. Terence Friedlander: Dr  Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases.Dr. Srikala Sridhar: Dr  Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers. The full webinar can be found on our website at: https://www.impactmedicom.com/video-capsules. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

Welcome to our podcast episode on external quality assurance (or eQA) for testing biomarkers in oncology, hosted by Anna Christofides. In this episode,  we discuss with Dr. Emina Torlakovic, the use of eQA to aid in the improvement of biomarker testing in Canada . Our Guest: Dr. Emina Torlakovic is a Professor in Department of Laboratory Medicine and Pathobiology at the University of Toronto. She is also a Staff Hematopathologist and Director of Biomarker Development and Quality Assurance at the University Health Network. Dr. Torlakovic is also a founding member of NordiQC, Canadian Immunohistochemistry Quality Control (CIQC), as well as the International Society for Immunohistochemistry and Molecular Morphology. She is Chair of the Canadian Association of Pathologists' National Standards Committee for High Complexity Testing and also co-directs CIQC. This podcast episode was sponsored by Merck, Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of urothelial carcinoma. In this fourth episode, we discuss the management of hyperglycemia associated with enfortumab vedotin, or EV.Our Guests:This fourth episode on the management of neuropathy is hosted by Dr Nimira Alimohamed, Medical Oncologist at the Tom Baker Cancer Centre, Calgary, AB and Clinical Assistant Professor in the Department of Medicine at the University of Calgary.  In this episode, Dr Alimohamed interviews Dr. Minna Woo, Professor in the Departments of Medicine, Institute of Medical Science, Immunology, and Pharmacology and Toxicology at the University of Toronto and Director of the Banting & Best Diabetes Centre. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma. In this second episode, we discuss the management of skin reactions associated with enfortumab vedotin, or EV. Our Guests:In this episode, Dr. Normand Blais, who is a medical oncologist and Director of clinical research in thoracic oncology at the CHUM and adjunct professor at McGill University in Montreal, QC interviews dermatology specialist, Dr. Joel Claveau. Dr. Joel Claveau is a dermatologist specializing in the diagnosis and treatment of Melanoma and Skin Cancers, and an Associate Professor with the Department of Medicine at Laval University guides us through this discussion. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma. In this first episode, we discuss the evolution of therapy from chemotherapy to treatment with novel therapies such as enfortumab vedotin, or EV. We then focus on the key clinical trials examining the efficacy and safety of EV for the treatment of urothelial carcinoma. Our Guests:We introduce the topic in our first episode with Dr. Normand Blais, who is a medical oncologist and Director of clinical research in thoracic oncology at the CHUM and adjunct professor at McGill University in Montreal, QC. Dr. Joel Claveau, a dermatologist specializing in the diagnosis and treatment of Melanoma and Skin Cancers, and an Associate Professor with the Department of Medicine at Laval University guides us through this discussion. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of urothelial carcinoma. In this third episode, we discuss the management of peripheral neuroptathy associated with enfortumab vedotin, or EV.Our Guests:This third episode on the management of neuropathy is hosted by Dr Srikala Sridhar, Professor in the Department of Medicine at the University of Toronto and a Genitourinary Medical  Oncologist at the Princess Margaret Cancer.  In this episode, Dr Sridhar interviews Dr Warren Mason, a Professor in the department of medicine at the University of Toronto and a neuro-oncologist at the Princess Margaret Cancer Center. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the latest updates in the treatment of CLL with Dr. Laurie Sehn, Dr. Matthew Davies, and Dr. Constantine Tam. Our Guests:Dr. SehnDr Sehn is a Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia. Dr. DavidsDr Davids is the Director of Clinical Research at the Division of Lymphoma at the Dana Farber Institute and Associate Professor of Medicine at Harvard Medical School.Dr. TamDr. Constantine Tam is a Professor of Hematology at the University of Melbourne, and Consultant Hematologist at the Peter MacCallum Cancer Centre in Melbourne, Australia. This podcast episode was sponsored by BeiGene Canada ULC.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the results of the ALPINE trial with Dr. Matthew Davies. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL. In this episode, Dr. Davids discusses the impact of the results of the ALPINE trial for clinical practice given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory CLL and SLL.Our Guest:Dr Davids is the Director of Clinical Research at the Division of Lymphoma at the Dana Farber Institute and Associate Professor of Medicine at Harvard Medical School. Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.This podcast episode was sponsored by BeiGene Canada ULC.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to our 13th podcast episode in the Precision Medicine Series. In this episode, hosted by Anna Christofides,  we discuss diagnostic, prognostic and predictive biomarkers for the treatment of endometrial cancer.  Our Guests:Dr. Jessica McAlpine, a Gynaecologic Oncologist and Division Head in the Division of Gynaecologic Oncology at the University of British ColumbiaDr. Mary Kinloch, a Gynaecologic Pathologist and Division Head of Pathology and Laboratory Medicine at the University of Saskatchewan This podcast episode was sponsored by Merck Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Live From ASH, New Orleans:In this very special episode of our podcast, we discuss the results of the ALPINE trial with Dr. Laurie Sehn, following the dissemination of the results during the late breaking abstract session at the American Society of Hematology meeting in New Orleans. Our Guest:Dr Sehn is a Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia. In this episode, Dr. Sehn discusses the impact of the results of the ALPINE trial for clinical practice in Canada given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.This podcast episode was sponsored by BeiGene Canada ULC.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Live From ASH, New Orleans:In this episode, Dr. Jennifer Brown discusses results of the phase 3 ALPINE trial, presented as a late breaking abstract at the American Society of Hematology (ASH) meeting 2022 in New Orleans, LA. Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582. Our Guest:Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.This podcast episode was sponsored by BeiGene Canada ULC.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this episode we discuss current and emerging systemic treatments for advanced, unresectable biliary tract cancers, as well as the barriers to accessing new treatments in Canada.  Our Guest:Dr. Howard Lim is a Medical Oncologist, specializing in the treatment of gastrointestinal cancers at the BC Cancer Agency in Vancouver and Clinical Associate Professor in the Faculty of Medicine at the University of British Columbia. This podcast episode was sponsored by AstraZeneca Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to our 12th episode in the precision medicine in oncology podcast series. In this episode we discuss diagnostic, prognostic and predictive biomarkers for the treatment of breast cancer.Our Guest: Our guest for this episode is Dr. David Cescon,  a Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Ontario, where his clinical practice is devoted to the care of patients with breast cancer.  This podcast episode was sponsored by Merck Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to IMPACT Medicom's podcast series on COVID-19 prophylaxis. In this third episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with cancer who are not able to mount a sufficient antibody response to vaccination. Our Guest:Our guest  is Dr. Cowan, who is an Associate Scientist at The Ottawa Hospital Research Institute and Assistant Professor at The University of Ottawa. Dr. Cowan is also cross-appointed as an Assistant Professor at the Department of Biochemistry, Microbiology and Immunology and a Physician for the Division of Infectious Diseases at The Ottawa Hospital in Ontario. Her clinical and research focus is on prevention of infection in immunocompromised patientsSponsored by AstraZeneca CanadaIf you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to IMPACT Medicom's podcast series on COVID-19 prophylaxis. In this third episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with cancer who are not able to mount a sufficient antibody response to vaccination. Our Guest:Our guest  is Dr. Dimas Yusuf, Medical Oncologist and specialist in general internal medicine at Pacific Specialty Care in Delta, BC. He is also the Managing Director of OncoCare Health Incorporated in Vancouver, BC, which delivers cutting edge technologies and insights to advance cancer care. Sponsored by AstraZeneca CanadaIf you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to IMPACT Medicom's podcast series on COVID-19 prophylaxis. In this second episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with hematological malignancies who are not able to mount a sufficient antibody response to vaccination.  Our Guest:Our guest  is Dr Laurie Sehn, Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia. Sponsored by AstraZeneca CanadaIf you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Bienvenue dans la série de balados d'IMPACT Medicom sur la prophylaxie contre la COVID-19.  Notre invitéeNotre invitée dans l'épisode d'aujourd'hui est Annick Dufour, chef adjointe au département de pharmacie du CISSS Montérégie-Centre, au Québec au niveau des soins pharmaceutiques, de la recherche clinique et de l'oncologique.  Elle est pharmacienne en oncologie depuis plusieurs années. Elle est également présidente du Comité d'évolution de la pratique des soins pharmaceutiques (CEPSP) du programme québécois de cancérologie du ministère de la Santé et des Services sociaux (MSSS) Sponsored by AstraZeneca CanadaIf you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to our podcast episode on the treatment of urothelial carcinoma. In this episode, hosted by Anna Christofides, we  discuss updated results of the Phase 3 EV-301 trial, presented at ASCO 2022, that examined the efficacy and safety of Enfortumab Vedotin, or EV, versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.  Our Guest:Our guest for this episode is Dr Nimira Alimohamed, Medical Oncologist and Clinical Associate Professor of Medicine at the University of Calgary and Medical Oncologist at the Tom Baker Cancer Centre in Calgary, Alberta. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this episode, we discuss immunotherapy treatment and biomarker testing for metastatic cervical cancer.  Our Guest:Dr. James Bentley is a Professor and Head of the Department of Obstetrics and Gynecology at Dalhousie University, Halifax, Canada. Dr. Bentley is Past President of the International Federation of Cervical Pathology and Colposcopy (IFCPC) and the Society of Canadian Colposcopists (SCC). He is also Past-President of the Society of Gynecologic Oncology of Canada (GOC). He serves on numerous national and provincial committees involved with cervical cancer screening and gynecological cancer. This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this episode of IMPACT Medicom's podcast series on immunotherapies in Head and Neck Squamous Cell Carcinoma, we discuss the medical oncologist's role in managing patients with HNSCC, and how immunotherapies fit in to their practice.Our Guest:Dr. Martin Smoragiewicz is a Medical Oncologist at the Odette Cancer Centre, part of Sunnybrook Health Sciences Centre in Toronto, Ontario. His clinical expertise is in Genitourinary and Head & Neck cancers and his research focuses on improving therapeutics, with a special interest in immunotherapy. Dr. Smoragiewicz is the principal investigator on numerous clinical trials, and the lead for Head & Neck clinical trials at the Odette Cancer Centre.This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to episode 11 of our Precision Medicine in Oncology series. In this episode, we discuss the development of a pan-Canadian consensus paper on the selection and use of PARP inhibitors for first-line maintenance treatment in ovarian cancer.Our Guest:Our guest for this episode is Dr. Anna Tinker, Medical Oncologist at BC Cancer in Vancouver, Canada. Dr. Tinker is also a Clinical Associate Professor in the Department of Medicine at the University of British Columbia.This podcast episode was sponsored by AstraZeneca Canada and Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to the second episode of IMPACT Medicom's podcast series on Immunotherapy in Head and Neck Squamous Cell Carcinomas (HNSCC). This episode includes a discussion of:The role of the surgical oncologist in managing patients with HNSCCHow immunotherapy fits into to the surgical oncologist's practice  Our Guest:Our guest is Dr. Antoine Eskander, a head and neck surgical oncologist at Sunnybrook Health Sciences Centre and Assistant professor in the department of otolaryngology at the University of Toronto. He is also an adjunct scientist at the Institute for Clinical Evaluative Sciences. This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

Welcome to the first episode of IMPACT Medicom's podcast series on Immunotherapy in Head and Neck Squamous Cell Carcinomas. This episode includes a discussion of:The role of the pathologist in the management of head and neck cancers PD-L1 testing as a predictive biomarker for immunotherapy in HNSCCImproving the testing process for PD-L1 Our Guest:Our guest is Dr. Matthew Cecchini, Pathologist in the Department of Pathology and Laboratory Medicine at London Health Sciences Centre and  Assistant Professor at Western University in London Ontario Canada. Dr. Cecchini  specializes in pulmonary, head and neck, and molecular pathology. His research interests include the application of digital and machine learning tools in pathology. This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

In this episode, we discuss the treatment of triple negative breast cancer (TNBC) with Dr. Stephen Chia. We cover:The use of immunotherapies to treat TNBCBiomarkers that can determine which patients will best respond to immunotherapiesThe challenges of testing for PDL-1Our Guest:Dr. Stephen Chia is a professor in the division of medical oncology and staff medical oncologist with BC Cancer, in Vancouver. He has held many leadership roles at BC Cancer, including Head of the Division of Medical Oncology UBC, Head of the Department of Clinical Research, BC Cancer, and Chair of the BC Cancer Breast Tumour Group. He has also been the Co-Chair of the Breast Disease Site for Canadian Cancer Trials Group (CCTG). This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

Bienvenue à la série de fichiers balados d'IMPACT Medicom sur la vaccination contre la COVID-19. Roula Drossis est l'animatrice de l'épisode d'aujourd'hui. Dans cet épisode, nous discutons de l'immunisation contre la COVID-19 et de la façon dont nous pouvons protéger nos populations les plus vulnérables qui ne sont pas en mesure de produire une réponse anticorps suffisante à la vaccination.  Notre invité:Notre invité à l'épisode d'aujourd'hui est le Dr Alex Carignan. Le Dr Carignan est médecin microbiologiste-infectiologue au Centre hospitalier universitaire de Sherbrooke. Il est également professeur titulaire et chercheur au département de microbiologie et d'infectiologie de l'Université de Sherbrooke. This podcast episode was sponsored by AstraZeneca Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

In this podcast series on pre- and post- COVID-19 prophylaxis, we discuss immunization against COVID-19 and how we can protect our most vulnerable populations who are not able to mount a sufficient antibody response to vaccination. In this fourth episode of the series, we discuss:Response to COVID-19 vaccines in the general populationResponse to COVID-19 vaccines in immunocompromised peopleThe impact of COVID-19 on patients with hematologic malignanciesThe potential role of pre- and post- COVID-19 exposure prophylaxis for people with hematologic malignanciesOur Guest:Our guest on today's episode is Dr. Carolyn Owen, who is an an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. This podcast episode was sponsored by AstraZeneca Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

In this podcast series on pre- and post- COVID-19 prophylaxis, we discuss immunization against COVID-19 and how we can protect our most vulnerable populations who are not able to mount a sufficient antibody response to vaccination. In this third episode of the series, we discuss:Response to COVID-19 vaccines in the general populationResponse to COVID-19 vaccines in immunocompromised peopleThe evolution of the pharmacist's role in immunizationThe potential role of pre- and post- COVID-19 exposure prophylaxis for people who are immunocompromisedOur Guest:Our guest is  Ajit Johal, who is a clinical instructor for the University of British Columbia Faculty of Pharmaceutical Sciences Program. Ajit has been providing immunizations and clinical education since 2012. In 2018, he started an organization called immunize.io, with a mission statement of "taking our best shot at immunizing the world". Through "immunize.io" he has worked with numerous organizations and communities to address “vaccine hesitancy” and improve access to vaccinations. Ajit also has his own podcast, which is available at: https://open.spotify.com/show/4BEzRqoLWLoQR5yM0pnW8I?si=Mc-5cOAjQNSjctNwTqtKmA&utm_source=copy-link This podcast episode was sponsored by AstraZeneca Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

In this podcast series on pre- and post- COVID-19 prophylaxis, we discuss immunization against COVID-19 and how we can protect our most vulnerable populations who are not able to mount a sufficient antibody response to vaccination. In this second episode of the series, we discuss:Response to COVID-19 vaccines in the general populationResponse to COVID-19 vaccines in people who have received a solid organ transplantationThe potential role of pre- and post- COVID-19 exposure prophylaxis for people with solid organ transplantsOur Guest:Our guest is Dr. Zain Chagla, who is an associate professor at McMaster University, co-medical director of infection control at St. Joseph's Healthcare Hamilton and a consultant in infection control at Woodstock General Hospital. Dr. Chagla's research and clinical interests include monoclonal antibody use in COVID-19, infections in renal transplantation, global health and tropical medicine, education and antimicrobial stewardship, and ultrasound in infectious diseases. This podcast episode was sponsored by AstraZeneca Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

In this podcast series on pre- and post- COVID-19 prophylaxis, we discuss immunization against COVID-19 and how we can protect our most vulnerable populations who are not able to mount a sufficient antibody response to vaccination. In this first episode of the series, we discuss:Response to COVID-19 vaccines in the general populationPopulations who have a reduced response to vaccinationThe difference between active and passive immunizationThe potential role of pre- and post- COVID-19 exposure prophylaxis for vulnerable populations Our Guest:Our guest  is Dr. Brian Conway, who is an infectious diseases specialist and the medical director of the Vancouver Infectious Diseases Centre, dedicated to the development and evaluation of systems of care for inner city vulnerable population. The models his team has established have led to increased access to HIV and HCV care as well as addiction services in a unique and durable manner. He is an adjunct professor in the Faculty of Health Sciences at Simon Fraser University. In 2012, he received the Queen Elizabeth II Diamond Jubilee Medal for long-standing service to the country in the field of HIV. In 2020, the Coalition for Global Hepatitis Elimination recognized Dr. Conway's group as one of 6 global elimination champions. In the times of COVID-19, he has been sought out by local and national media to help Canadians make sense of the pandemic. Through generous funding from the Public Health Agency of Canada, he is currently involved in optimizing vaccine and treatment understanding and uptake among inner city residents. This podcast episode was sponsored by AstraZeneca Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

In this episode of IMPACT Medicom's Precision Medicine in Oncology podcast series, we discuss the evolving biomarker landscape in gastrointestinal malignancies and some of the advantages and challenges of implementing and accessing biomarker testing. Our guest:Dr. Rosalyn Juergens is a medical oncologist with clinical expertise in lung and esophageal cancer. She was on the faculty at The Johns Hopkins Medical Institute from 2007-2010 until she joined the faculty at McMaster University in 2011. Dr. Juergens' leadership roles include serving as chair of the Lung Disease Site Team and Head of the Department of Clinical Trials at the Juravinski Cancer Centre in Hamilton, Ontario. She is also the chair of the Executive Committee of the Canadian Cancer Trials Group Investigational New Drug Committee and Medical Advisory Committee Chair for Lung Cancer Canada. Dr. Juergens' research interests involve improving therapeutics and diagnostics in cancer, with a focus on developmental therapeutics and Phase I and II clinical trials.This podcast episode was sponsored by Merck Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

Welcome to episode 9 of IMPACT Medicom's podcast series on Precision Medicine in Oncology, the second episode in a 3-part series on ovarian cancer. This episode, hosted by IMPACT Medicom's Sarah Doucette, features a debate on whether first-line maintenance therapy with PARP inhibitors can be considered a curative strategy in patients with advanced, BRCA-mutated epithelial ovarian cancer. Our Guests:Dr. Taymaa May Taymaa May is a surgical scientist at the University Health Network and an Associate Professor at the University of Toronto. Dr. May is the surgical oncology lead for Toronto central south, Ontario Health/Cancer Care Ontario and the chair of the Gynecologic Oncology Group of Ontario. She is the director of clinical specialty programs in the department of surgical oncology and a member of the Princess Margaret executive. She is also the current chair of the Gynecologic Oncology of Canada's (GOC) Annual General Meeting and is a member of GOC's board of directors. Dr. May's research focuses on surgical innovation and translational research in ovarian cancer.Dr. James Bentley Dr. James Bentley is a Professor and Head of the Department of Obstetrics and Gynaecology at Dalhousie University. He is a Past President of the International Federation of Cervical Pathology and Colposcopy (IFCPC), the Society of Gynaecologic Oncology of Canada (GOC), and the Society of Canadian Colposcopists, and is the past Chair of the Royal College Nucleus Committee for Gynecologic Oncology. He continues to serve on numerous national and provincial committees involved with cervical cancer screening and gynecological cancer. Dr. Bentley's clinical interests lie in the field of cervical cancer prevention, colposcopy, clinical trials including the application of HPV Vaccines and chemotherapy trials.Links:SOLO-1 5-year update: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00531-3/fulltextCorrelation between BRCA status and surgical cytoreduction: https://www.gynecologiconcology-online.net/article/S0090-8258(21)00540-0/fulltextThis podcast episode was sponsored by AstraZeneca Canada and Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to episode 8 of IMPACT Medicom's podcast series on Precision Medicine in Oncology, the first in a series of episodes focusing on ovarian cancer. In this episode, we discuss the importance of BRCA testing for patients with advanced epithelial ovarian cancer and how national initiatives have helped to improve BRCA testing standards across the country. Our Guests:Dr. Janice Kwon, Gynecologic Oncologist at Vancouver Coastal Health and Vice Head and Professor in the Department of Obstetrics and Gynecology at the University of British Columbia. Dr. Kwon serves as Chair of both the Priority and Evaluations Committee at BC Cancer and the National BRCA Collaborative. Her expertise is in hereditary cancer syndromes and conducting cost-effectiveness analyses of testing criteria and risk-reducinginterventions.Dr. Alon Altman, Gynecologic Oncologist and Professor at the University of Manitoba, and the Winnipeg Health Sciences Centre/Cancercare Manitoba.  Dr. Altman is the president elect for the Society of Gynecologic Oncology of Canada (the GOC). He is actively involved in multiple other university, national and international committees including serving as program director for the department of Obstetrics and Gynecology, chair of the University Medical Group (UMG), vice chair for the Medical Management Safety Committee (MMSC) at CancerCare Manitoba, and Gynecologic oncology track lead for the FIGO 2021 Scientific planning committee.This podcast episode was sponsored by AstraZeneca Canada and Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this seventh episode of our podcast series on precision medicine, hosted by Anna Christofides, we discuss genomic testing in prostate cancer. Our episode focuses on the evolution and uptake of genetic testing in prostate cancer. We discuss testing for homologous recombination repair (HRR) genes and their association with prognosis and influence on treatment decisions. We also discuss somatic vs germline testing and who is responsible for ordering genomic tests. Our guest:Our guest on today's episode is Dr. Neil Fleshner, who is the Martin Barkin Chair and a Professor of Surgery at the Division of Urology at the University of Toronto in Toronto, Ontario. He is also affiliated with Sunnybrook Hospital, Mount Sinai Hospital, Princess Margaret Cancer Centre (UHN), and the Toronto General Hospital (UHN).This podcast episode was sponsored by AstraZeneca Canada and Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com